A GLP-1 analogue is a lab-engineered molecule built to closely resemble the body's own GLP-1 hormone, then chemically tweaked so it survives in the bloodstream for hours or days instead of minutes. Semaglutide, liraglutide, and dulaglutide are the best-known true GLP-1 analogues. This guide explains what makes a drug an analogue, how the molecules are altered and manufactured, and which approved medicines actually qualify.
One older analogue worth knowing is Sanofi's GLP-1 lixisenatide.
What is a GLP-1 analogue?
In drug chemistry, an analogue is a molecule that is structurally similar to a reference compound, in this case native human GLP-1, but with deliberate modifications. A GLP-1 analogue keeps most of the natural hormone's amino-acid sequence, so it still fits and activates the GLP-1 receptor, but it carries changes that fix the hormone's biggest weakness: it falls apart almost instantly.
The natural hormone is degraded by an enzyme called DPP-4 within roughly one to two minutes, according to physiology references from the National Center for Biotechnology Information. An analogue is essentially native GLP-1 rebuilt to dodge that enzyme and linger long enough to be a practical medicine.
How is an analogue different from the natural hormone?
Two engineering tricks turn a fragile hormone into a long-acting drug. Both are documented in the peer-reviewed history of these molecules (for example, the open-access review "The Discovery and Development of Liraglutide and Semaglutide," published in Frontiers in Endocrinology and archived on PubMed Central).
DPP-4 resistance
DPP-4 cuts GLP-1 at a specific spot near one end of the peptide. Analogues change the amino acid at or near that spot so the enzyme can no longer make the cut. Semaglutide, for instance, swaps the amino acid at position 8 for a modified one (aminoisobutyric acid), which blocks DPP-4 from cleaving it.
Albumin binding (fatty-acid acylation)
The second trick is to attach a fatty-acid chain to the peptide. That chain lets the drug grab onto albumin, the most abundant protein in your blood, and ride along with it. Bound to albumin, the molecule is shielded from being filtered out by the kidneys and released only slowly. This single design choice is the main reason semaglutide lasts about a week while the natural hormone lasts minutes.
How are GLP-1 analogues actually made?
GLP-1 analogues are peptides, so manufacturing combines biology and chemistry:
- Build the peptide backbone. The core amino-acid chain is produced either by chemical synthesis or, for some products, by recombinant fermentation, in which engineered yeast or bacteria are programmed to assemble the peptide.
- Attach the modifications. The fatty-acid chain and any linker are added chemically (a step called acylation) at a precise position on the peptide.
- Purify and formulate. The finished molecule is purified to pharmaceutical grade and formulated for injection (or, for oral semaglutide, combined with an absorption enhancer so a fraction survives the stomach).
This is more involved than making a simple small-molecule pill, which is part of why brand-name GLP-1 analogues are expensive to produce. Each step also has to be tightly controlled, because the position of a single fatty-acid chain or amino-acid substitution determines whether the finished molecule survives in the body and binds the receptor properly. Small manufacturing differences are a major reason regulators scrutinize compounded and copycat versions so closely.
Which approved drugs are true GLP-1 analogues?
A "true" GLP-1 analogue is built from the human GLP-1 sequence. The clearest examples and their key properties:
| Drug (generic) | Brand names | Half-life | Dosing |
|---|---|---|---|
| Liraglutide | Victoza, Saxenda | ~13 hours | Once daily |
| Semaglutide | Ozempic, Wegovy, Rybelsus | ~160-165 hours (~1 week) | Weekly (oral form daily) |
| Dulaglutide | Trulicity | ~5 days | Once weekly |
Liraglutide, the first of the modern human-GLP-1 analogues, is covered in our Saxenda (liraglutide) guide. Semaglutide is the most prescribed member of the group today. For a wider view of what shares this drug class, see drugs similar to semaglutide.
Why does half-life extension matter so much?
The whole point of making an analogue is the half-life (how long the drug stays active). Native GLP-1 lasts minutes; liraglutide lasts about 13 hours, allowing once-daily dosing; semaglutide and dulaglutide last around a week, allowing once-weekly injections. Longer-acting molecules mean fewer injections, steadier drug levels, and generally better real-world adherence. You can see how this plays out for a specific molecule in our explainer on tirzepatide's half-life.
The trade-off is that a long half-life also means the drug clears slowly after you stop, which matters for planning around surgery, pregnancy, or side effects. As a rough rule, it takes about five half-lives for a drug to leave the system, so a weekly analogue can still be measurably present for a month or more after the final dose. That is one reason clinicians ask about GLP-1 use well before scheduled procedures, and why side effects do not vanish the moment you skip an injection.
Which "GLP-1 drugs" are NOT human GLP-1 analogues?
This is where labels get slippery, and it is worth being precise.
- Exenatide and lixisenatide are based on exendin-4, a peptide discovered in the saliva of the Gila monster lizard. Exendin-4 shares only about 53% of its sequence with human GLP-1, so although these drugs activate the GLP-1 receptor, they are exendin analogues, not human-GLP-1 analogues.
- Tirzepatide is built on the GIP hormone backbone and is best described as a GIP analogue that also activates the GLP-1 receptor, making it a dual agonist rather than a GLP-1 analogue.
So every one of these is a GLP-1 receptor agonist, but not every one is a GLP-1 analogue. That distinction trips up a lot of readers, and we untangle it fully in GLP-1 analogue vs. GLP-1 agonist. The pipeline of next-generation molecules, several of which blur these categories further, is tracked in new GLP-1 drugs. The shared -glutide naming convention is decoded in what the "-glutide" suffix means.
Frequently Asked Questions
Is semaglutide a GLP-1 analogue or a GLP-1 agonist?
Both. Structurally it is a human GLP-1 analogue (about 94% of the native sequence), and functionally it is a GLP-1 receptor agonist because it activates the receptor. The two labels describe different things about the same molecule.
Is tirzepatide a GLP-1 analogue?
Not in the strict sense. Its backbone is based on the GIP hormone, so it is usually called a GIP analogue and a dual GIP/GLP-1 receptor agonist rather than a GLP-1 analogue.
Are GLP-1 analogues the same as "biosimilars" or generics?
No. An analogue is the original engineered molecule. A generic or biosimilar is a later copy of an already-approved drug. As patents expire, copies of these analogues are expected to appear, but the term "analogue" refers to the relationship to the natural hormone, not to the patent status.
Why are analogues injected instead of taken as pills?
Peptides are normally destroyed by stomach acid and digestive enzymes. Most analogues are injected to bypass that. Oral semaglutide is the exception, achieved by adding a special absorption enhancer, though only a small fraction is absorbed.
References
- Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. StatPearls, NCBI Bookshelf. (Mechanism, DPP-4 degradation of native GLP-1, incretin effect.)
- U.S. Food and Drug Administration. WEGOVY (semaglutide) injection — Prescribing Information. (Semaglutide pharmacokinetics, ~1-week half-life, fatty-acid acylation.)
This article is for general education and is not medical advice. Talk to a licensed clinician before starting, stopping, or changing any medication.